Followers | 682 |
Posts | 17,338 |
Boards Moderated | 2 |
Alias Born | 03/28/2011 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just some consolidation lol. Watch for another run. Big buys coming in now.
Some re griping for the next leg up.
Is this a 10 bagger yet?
Thank you for your service.
Are you serving over seas ?
No offence but do you really think someone can tell you what a penny stock will do? We would like for it to hold here then go up. Honestly no one can tell you what a stock will or will not do. the good thing is your in the right place PHAR is a great company to have an investment in. Major upside with low risk,float, and debt !!!!
PHAR out ! Were green over the weekend !!! Is monday closed for trading ?
I think short selling shouldnt be allowed. If they are my shares that I bought why should someone be able to BORROW them ? This just stinks all the way around. Go PHAR soon the longs will have there day.
Bayer to buy PHAR in my opinion.
Here we go buckle up no wonder they drove PPS down yesterday
see post 6193
If it goes to .0001 then just buy 1 million shares sell for .0002 then you make all your money back it's simple math. At this time means at this time. Do you really think PHAR is selling shares ?? Oh look someone just sold 70$ worth of shares @ .0175 that was company dilution !! Lol come on man. I've seen company dilution and it hasn't happened here yet!
He's been saying this for sometime now in multiple posts. I asked him to prove it and I got no response . I'm with you on the NO dilution. Just a couple of frantic investors with wild assumptions, moving on now.
PHAR there have been more buys than sells today so PHAR. MM have dropped it down and sold 70$ worth of shares @ .0175 level to paint this as a get out now panic to see if anyone bites and sells at these levels. They are aware of how this will fly once things get going !! Don't be fooled they want your cheepies !! They want you to be scared and sell down here !! We will bounce right back up !!
PHAR thank you !!
PHAR a little chasing of the bid and thin after .024 ?? I don't have level 2 here at work can someone catch me up to speed on how the bid ask is shaping up ??
PHAR my point exactly ! Ive been trying to point this out 30 BILLION not million but BILLION !!!
PHAR wow nice DD ! Count me in as s shareholder . I want in on this ground floor opportunity !
PHAR welcome ! You are in at a good time .
Congratulations ! go PHAR
PHAR what is the first priority of someone in a short position ? Give up ? Discredit the company by saying they are selling shares . This makes investors afraid of the company's agenda . Problem with you crow is you have no DD you have proven your intelligence and you will eat crow . Prove the company sold shares. Provide something please so I can be wrong !!
PHAR you just showed everyone on this board how much you know about stocks ! I'm a newbie and even I know big news doesn't always drive the PPS up !! Often times it provides a selling opportunity for those to make a profit .
PHAR I couldnt agree with you more twisting the truth from the begining of time. Now Back to DD . First of all bashers,for you to say here insert link then have a good day. What is that ? Thats not DD the only scam is you and your pitiful effort. Or what we should label what proceeds from your keyboard as is spam . Well we all know what happens to spam. it gets thrown in the junk box and deleted. So the only scam in PHAR is you NON believers with your wimpy efforts to discredit PHAR with NO REAL DD. Just copy and pasting of old junk links aka spam on our board doesnt mean DD on your part. Go PHAR or go home.
PHAR nice DD God bless you.
PHAR yesterday closed green. Today closed red. Patience is a virtue it builds character.
PHAR is the most technically sound penny stock I've ran across so PHAR
PHAR GM what a beautiful and wonderful day it is. Let's slowly climb up today . Remember to slap that ask !! And sell @ the ask !! Please no bid whacking !! DO NOT SELL THE BID let's do everything we can to take this back over from the short and pump n dumpers !! Have a great day go PHAR !!
News***PHAR .023X.025 3X2
PHAR= RUNNING on NEWS = +20%
PHAR(.021) NEWS OUT NOW!!!
Quote:
PharmStar will begin moving into the new facility immediately, and has been preparing for the move over the last 30 days. PharmStar CEO Howard Phykitt founded Granutec, Inc. in 1985 in Wilson, NC before selling the company in 1989. He remained with the company through 1991. Mr. Phykitt then started Health Corporation , developing and marketing the original form of Aquaprin.
The Company did not issue any type of a new debt instrument, nor did the Company dilute its existing common share capital structure in order to finance the transaction, which is consistent with the company's objective of minimizing future dilution of its shareholder base.
http://finance.yahoo.com/news/PharmStar-Pharmaceuticals-Inc-iw-2427996609.html?x=0
-----------------------------
PHAR Property Appraisal Valued at $32 Million
Date : 05/09/2011 @ 1:21PM
Source : MarketWire
Stock : PharmStar Pharmaceuticals, Inc. (PHAR)
Quote : 0.032 0.002 (6.67%) @ 2:02PM
http://news.morningstar.com/all/market-wire/11753738/pharmstar-pharmaceuticals-receives-updated-intellectual-property-appraisal-valued-at-32-million.aspx
((wow~DD))= http://t.co/k1ffD7a , http://t.co/8eGBQGn
PharmStar Pharmaceuticals Receives Updated Intellectual Property Appraisal Valued at $32 Million
Pharmstar Pharm (USOTC:PHAR)
Intraday Stock Chart
Today : Monday 9 May 2011
PharmStar Pharmaceuticals, Inc., (PINKSHEETS: PHAR) (the "Company"), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today announced that it has received an updated appraisal for the Company's intellectual property. The new report states that the intellectual property associated with the patent, know-how and trademark positions of PharmStar Pharmaceuticals is valued at $32 million
. The report was filed as a supplemental information disclosure with the OTC Markets on May 6, 2011 and may be found at www.otcmarkets.com/stock/PHAR/financials, under the "Supplemental Information -- PharmStar IP Valuation."
The appraisal report was provided by Hultquist IP, a firm that represents clients in intellectual property matters in a wide variety of technologies, including: chemical, biological, electronic, solid-state, mechanical, and information technologies. According to the Hultquist report, "This total present value of $32 million is determined to be the value of the intellectual property rights associated with the Aquaprin™ product and the Insta-prin™ applicator product, since in the absence of the intellectual property applicable to these products, commercialization would not be viable, and there would be no barrier to entry to far larger competitors with correspondingly larger resources. The exclusionary rights associated with the proprietary patent position of PSP, together with the branding trademarks, and substantial know-how of Howard Phykitt, warrant such valuation. We therefore conclude that the intellectual property rights relating to the Aquaprin™ product and the Insta-prin™ applicator product are fairly valued at $32 million."
On April 28, 2011, the Company filed its Quarterly Report for the first quarter of 2011. In the report, the Company recognized the value of its Intellectual Property and Patents, Research and Development of Patents at a total of $13,104,549. The Company will continue to list these assets at their imputed book value, rather than the determined market value pursuant to the report.
"Though we are pleased with the valuation ascribed to the Aquaprin™ product line by Hultquist IP, we believe that the prudent course of action at this time is to continue to show the value of our core assets at book value. We will do so until such a time as the Company is in full production, or has a clear and substantial reason to modify the said valuation," stated Howard Phykitt, Chairman and CEO of PharmStar.
About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Rocky Mount, NC. For more information, visit www.pharmstarinc.com.
PHAR Financials out before yesterdays close showing
31M assets 50k liabilities
12m float as of 4-8
Clean balance sheet
FDA Approved "Aquaprin"
also..
Just upgraded to Pinksheets "Current Information" 4-14
Buying a NEW FDA Approved facility
CEO has put in writing NO DILUTION for at least 6 mos(HUGE)
Insiders shares restricted for min 1yr(awesome)
Quote:
The Company has received an offer to purchase the building, and is currently assessing the offer. Mr. Phykitt concluded, "I made a commitment to shareholders when we restructured the capitalization table that the Company has no need to dilute its common stock for at least the next six months. This decision will not affect that commitment."
http://ih.advfn.com/p.php?pid=nmona&article=47333789
3.There is no need to increase Authorized Shares at this time, and the company does not anticipate having to increase its Authorized anytime in the near future.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62802709
just look under Liabilities:
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=48798
Accounts payable-0-
Notes payable-0-
Notes payable to related parties-0-
Legal fees payable-0-
Licenses deposit Pharma Cap= 50,000
The ONLY Liability that Pharmstar has PERIOD is a $50,000 licensing fee for a Pharma bottle cap for the companies Instaprin product.
Why PHAR seen here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62514099
http://www.pharmstarinc.com/why_aquaprin.html
News***PHAR .023X.025 3X2
PHAR= RUNNING on NEWS = +20%
PHAR(.021) NEWS OUT NOW!!!
Quote:
PharmStar will begin moving into the new facility immediately, and has been preparing for the move over the last 30 days. PharmStar CEO Howard Phykitt founded Granutec, Inc. in 1985 in Wilson, NC before selling the company in 1989. He remained with the company through 1991. Mr. Phykitt then started Health Corporation , developing and marketing the original form of Aquaprin.
The Company did not issue any type of a new debt instrument, nor did the Company dilute its existing common share capital structure in order to finance the transaction, which is consistent with the company's objective of minimizing future dilution of its shareholder base.
http://finance.yahoo.com/news/PharmStar-Pharmaceuticals-Inc-iw-2427996609.html?x=0
-----------------------------
PHAR Property Appraisal Valued at $32 Million
Date : 05/09/2011 @ 1:21PM
Source : MarketWire
Stock : PharmStar Pharmaceuticals, Inc. (PHAR)
Quote : 0.032 0.002 (6.67%) @ 2:02PM
http://news.morningstar.com/all/market-wire/11753738/pharmstar-pharmaceuticals-receives-updated-intellectual-property-appraisal-valued-at-32-million.aspx
((wow~DD))= http://t.co/k1ffD7a , http://t.co/8eGBQGn
PharmStar Pharmaceuticals Receives Updated Intellectual Property Appraisal Valued at $32 Million
Pharmstar Pharm (USOTC:PHAR)
Intraday Stock Chart
Today : Monday 9 May 2011
PharmStar Pharmaceuticals, Inc., (PINKSHEETS: PHAR) (the "Company"), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today announced that it has received an updated appraisal for the Company's intellectual property. The new report states that the intellectual property associated with the patent, know-how and trademark positions of PharmStar Pharmaceuticals is valued at $32 million
. The report was filed as a supplemental information disclosure with the OTC Markets on May 6, 2011 and may be found at www.otcmarkets.com/stock/PHAR/financials, under the "Supplemental Information -- PharmStar IP Valuation."
The appraisal report was provided by Hultquist IP, a firm that represents clients in intellectual property matters in a wide variety of technologies, including: chemical, biological, electronic, solid-state, mechanical, and information technologies. According to the Hultquist report, "This total present value of $32 million is determined to be the value of the intellectual property rights associated with the Aquaprin™ product and the Insta-prin™ applicator product, since in the absence of the intellectual property applicable to these products, commercialization would not be viable, and there would be no barrier to entry to far larger competitors with correspondingly larger resources. The exclusionary rights associated with the proprietary patent position of PSP, together with the branding trademarks, and substantial know-how of Howard Phykitt, warrant such valuation. We therefore conclude that the intellectual property rights relating to the Aquaprin™ product and the Insta-prin™ applicator product are fairly valued at $32 million."
On April 28, 2011, the Company filed its Quarterly Report for the first quarter of 2011. In the report, the Company recognized the value of its Intellectual Property and Patents, Research and Development of Patents at a total of $13,104,549. The Company will continue to list these assets at their imputed book value, rather than the determined market value pursuant to the report.
"Though we are pleased with the valuation ascribed to the Aquaprin™ product line by Hultquist IP, we believe that the prudent course of action at this time is to continue to show the value of our core assets at book value. We will do so until such a time as the Company is in full production, or has a clear and substantial reason to modify the said valuation," stated Howard Phykitt, Chairman and CEO of PharmStar.
About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Rocky Mount, NC. For more information, visit www.pharmstarinc.com.
PHAR Financials out before yesterdays close showing
31M assets 50k liabilities
12m float as of 4-8
Clean balance sheet
FDA Approved "Aquaprin"
also..
Just upgraded to Pinksheets "Current Information" 4-14
Buying a NEW FDA Approved facility
CEO has put in writing NO DILUTION for at least 6 mos(HUGE)
Insiders shares restricted for min 1yr(awesome)
Quote:
The Company has received an offer to purchase the building, and is currently assessing the offer. Mr. Phykitt concluded, "I made a commitment to shareholders when we restructured the capitalization table that the Company has no need to dilute its common stock for at least the next six months. This decision will not affect that commitment."
http://ih.advfn.com/p.php?pid=nmona&article=47333789
3.There is no need to increase Authorized Shares at this time, and the company does not anticipate having to increase its Authorized anytime in the near future.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62802709
just look under Liabilities:
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=48798
Accounts payable-0-
Notes payable-0-
Notes payable to related parties-0-
Legal fees payable-0-
Licenses deposit Pharma Cap= 50,000
The ONLY Liability that Pharmstar has PERIOD is a $50,000 licensing fee for a Pharma bottle cap for the companies Instaprin product.
Why PHAR seen here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62514099
http://www.pharmstarinc.com/why_aquaprin.html
News***PHAR .023X.025 3X2
PHAR= RUNNING on NEWS = +20%
PHAR(.021) NEWS OUT NOW!!!
Quote:
PharmStar will begin moving into the new facility immediately, and has been preparing for the move over the last 30 days. PharmStar CEO Howard Phykitt founded Granutec, Inc. in 1985 in Wilson, NC before selling the company in 1989. He remained with the company through 1991. Mr. Phykitt then started Health Corporation , developing and marketing the original form of Aquaprin.
The Company did not issue any type of a new debt instrument, nor did the Company dilute its existing common share capital structure in order to finance the transaction, which is consistent with the company's objective of minimizing future dilution of its shareholder base.
http://finance.yahoo.com/news/PharmStar-Pharmaceuticals-Inc-iw-2427996609.html?x=0
-----------------------------
PHAR Property Appraisal Valued at $32 Million
Date : 05/09/2011 @ 1:21PM
Source : MarketWire
Stock : PharmStar Pharmaceuticals, Inc. (PHAR)
Quote : 0.032 0.002 (6.67%) @ 2:02PM
http://news.morningstar.com/all/market-wire/11753738/pharmstar-pharmaceuticals-receives-updated-intellectual-property-appraisal-valued-at-32-million.aspx
((wow~DD))= http://t.co/k1ffD7a , http://t.co/8eGBQGn
PharmStar Pharmaceuticals Receives Updated Intellectual Property Appraisal Valued at $32 Million
Pharmstar Pharm (USOTC:PHAR)
Intraday Stock Chart
Today : Monday 9 May 2011
PharmStar Pharmaceuticals, Inc., (PINKSHEETS: PHAR) (the "Company"), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today announced that it has received an updated appraisal for the Company's intellectual property. The new report states that the intellectual property associated with the patent, know-how and trademark positions of PharmStar Pharmaceuticals is valued at $32 million
. The report was filed as a supplemental information disclosure with the OTC Markets on May 6, 2011 and may be found at www.otcmarkets.com/stock/PHAR/financials, under the "Supplemental Information -- PharmStar IP Valuation."
The appraisal report was provided by Hultquist IP, a firm that represents clients in intellectual property matters in a wide variety of technologies, including: chemical, biological, electronic, solid-state, mechanical, and information technologies. According to the Hultquist report, "This total present value of $32 million is determined to be the value of the intellectual property rights associated with the Aquaprin™ product and the Insta-prin™ applicator product, since in the absence of the intellectual property applicable to these products, commercialization would not be viable, and there would be no barrier to entry to far larger competitors with correspondingly larger resources. The exclusionary rights associated with the proprietary patent position of PSP, together with the branding trademarks, and substantial know-how of Howard Phykitt, warrant such valuation. We therefore conclude that the intellectual property rights relating to the Aquaprin™ product and the Insta-prin™ applicator product are fairly valued at $32 million."
On April 28, 2011, the Company filed its Quarterly Report for the first quarter of 2011. In the report, the Company recognized the value of its Intellectual Property and Patents, Research and Development of Patents at a total of $13,104,549. The Company will continue to list these assets at their imputed book value, rather than the determined market value pursuant to the report.
"Though we are pleased with the valuation ascribed to the Aquaprin™ product line by Hultquist IP, we believe that the prudent course of action at this time is to continue to show the value of our core assets at book value. We will do so until such a time as the Company is in full production, or has a clear and substantial reason to modify the said valuation," stated Howard Phykitt, Chairman and CEO of PharmStar.
About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Rocky Mount, NC. For more information, visit www.pharmstarinc.com.
PHAR Financials out before yesterdays close showing
31M assets 50k liabilities
12m float as of 4-8
Clean balance sheet
FDA Approved "Aquaprin"
also..
Just upgraded to Pinksheets "Current Information" 4-14
Buying a NEW FDA Approved facility
CEO has put in writing NO DILUTION for at least 6 mos(HUGE)
Insiders shares restricted for min 1yr(awesome)
Quote:
The Company has received an offer to purchase the building, and is currently assessing the offer. Mr. Phykitt concluded, "I made a commitment to shareholders when we restructured the capitalization table that the Company has no need to dilute its common stock for at least the next six months. This decision will not affect that commitment."
http://ih.advfn.com/p.php?pid=nmona&article=47333789
3.There is no need to increase Authorized Shares at this time, and the company does not anticipate having to increase its Authorized anytime in the near future.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62802709
just look under Liabilities:
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=48798
Accounts payable-0-
Notes payable-0-
Notes payable to related parties-0-
Legal fees payable-0-
Licenses deposit Pharma Cap= 50,000
The ONLY Liability that Pharmstar has PERIOD is a $50,000 licensing fee for a Pharma bottle cap for the companies Instaprin product.
Why PHAR seen here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62514099
http://www.pharmstarinc.com/why_aquaprin.html
News***PHAR .023X.025 3X2
PHAR= RUNNING on NEWS = +20%
PHAR(.021) NEWS OUT NOW!!!
Quote:
PharmStar will begin moving into the new facility immediately, and has been preparing for the move over the last 30 days. PharmStar CEO Howard Phykitt founded Granutec, Inc. in 1985 in Wilson, NC before selling the company in 1989. He remained with the company through 1991. Mr. Phykitt then started Health Corporation , developing and marketing the original form of Aquaprin.
The Company did not issue any type of a new debt instrument, nor did the Company dilute its existing common share capital structure in order to finance the transaction, which is consistent with the company's objective of minimizing future dilution of its shareholder base.
http://finance.yahoo.com/news/PharmStar-Pharmaceuticals-Inc-iw-2427996609.html?x=0
-----------------------------
PHAR Property Appraisal Valued at $32 Million
Date : 05/09/2011 @ 1:21PM
Source : MarketWire
Stock : PharmStar Pharmaceuticals, Inc. (PHAR)
Quote : 0.032 0.002 (6.67%) @ 2:02PM
http://news.morningstar.com/all/market-wire/11753738/pharmstar-pharmaceuticals-receives-updated-intellectual-property-appraisal-valued-at-32-million.aspx
((wow~DD))= http://t.co/k1ffD7a , http://t.co/8eGBQGn
PharmStar Pharmaceuticals Receives Updated Intellectual Property Appraisal Valued at $32 Million
Pharmstar Pharm (USOTC:PHAR)
Intraday Stock Chart
Today : Monday 9 May 2011
PharmStar Pharmaceuticals, Inc., (PINKSHEETS: PHAR) (the "Company"), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today announced that it has received an updated appraisal for the Company's intellectual property. The new report states that the intellectual property associated with the patent, know-how and trademark positions of PharmStar Pharmaceuticals is valued at $32 million
. The report was filed as a supplemental information disclosure with the OTC Markets on May 6, 2011 and may be found at www.otcmarkets.com/stock/PHAR/financials, under the "Supplemental Information -- PharmStar IP Valuation."
The appraisal report was provided by Hultquist IP, a firm that represents clients in intellectual property matters in a wide variety of technologies, including: chemical, biological, electronic, solid-state, mechanical, and information technologies. According to the Hultquist report, "This total present value of $32 million is determined to be the value of the intellectual property rights associated with the Aquaprin™ product and the Insta-prin™ applicator product, since in the absence of the intellectual property applicable to these products, commercialization would not be viable, and there would be no barrier to entry to far larger competitors with correspondingly larger resources. The exclusionary rights associated with the proprietary patent position of PSP, together with the branding trademarks, and substantial know-how of Howard Phykitt, warrant such valuation. We therefore conclude that the intellectual property rights relating to the Aquaprin™ product and the Insta-prin™ applicator product are fairly valued at $32 million."
On April 28, 2011, the Company filed its Quarterly Report for the first quarter of 2011. In the report, the Company recognized the value of its Intellectual Property and Patents, Research and Development of Patents at a total of $13,104,549. The Company will continue to list these assets at their imputed book value, rather than the determined market value pursuant to the report.
"Though we are pleased with the valuation ascribed to the Aquaprin™ product line by Hultquist IP, we believe that the prudent course of action at this time is to continue to show the value of our core assets at book value. We will do so until such a time as the Company is in full production, or has a clear and substantial reason to modify the said valuation," stated Howard Phykitt, Chairman and CEO of PharmStar.
About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Rocky Mount, NC. For more information, visit www.pharmstarinc.com.
PHAR Financials out before yesterdays close showing
31M assets 50k liabilities
12m float as of 4-8
Clean balance sheet
FDA Approved "Aquaprin"
also..
Just upgraded to Pinksheets "Current Information" 4-14
Buying a NEW FDA Approved facility
CEO has put in writing NO DILUTION for at least 6 mos(HUGE)
Insiders shares restricted for min 1yr(awesome)
Quote:
The Company has received an offer to purchase the building, and is currently assessing the offer. Mr. Phykitt concluded, "I made a commitment to shareholders when we restructured the capitalization table that the Company has no need to dilute its common stock for at least the next six months. This decision will not affect that commitment."
http://ih.advfn.com/p.php?pid=nmona&article=47333789
3.There is no need to increase Authorized Shares at this time, and the company does not anticipate having to increase its Authorized anytime in the near future.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62802709
just look under Liabilities:
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=48798
Accounts payable-0-
Notes payable-0-
Notes payable to related parties-0-
Legal fees payable-0-
Licenses deposit Pharma Cap= 50,000
The ONLY Liability that Pharmstar has PERIOD is a $50,000 licensing fee for a Pharma bottle cap for the companies Instaprin product.
Why PHAR seen here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62514099
http://www.pharmstarinc.com/why_aquaprin.html
News***PHAR .023X.025 3X2
PHAR= RUNNING on NEWS = +20%
PHAR(.021) NEWS OUT NOW!!!
Quote:
PharmStar will begin moving into the new facility immediately, and has been preparing for the move over the last 30 days. PharmStar CEO Howard Phykitt founded Granutec, Inc. in 1985 in Wilson, NC before selling the company in 1989. He remained with the company through 1991. Mr. Phykitt then started Health Corporation , developing and marketing the original form of Aquaprin.
The Company did not issue any type of a new debt instrument, nor did the Company dilute its existing common share capital structure in order to finance the transaction, which is consistent with the company's objective of minimizing future dilution of its shareholder base.
http://finance.yahoo.com/news/PharmStar-Pharmaceuticals-Inc-iw-2427996609.html?x=0
-----------------------------
PHAR Property Appraisal Valued at $32 Million
Date : 05/09/2011 @ 1:21PM
Source : MarketWire
Stock : PharmStar Pharmaceuticals, Inc. (PHAR)
Quote : 0.032 0.002 (6.67%) @ 2:02PM
http://news.morningstar.com/all/market-wire/11753738/pharmstar-pharmaceuticals-receives-updated-intellectual-property-appraisal-valued-at-32-million.aspx
((wow~DD))= http://t.co/k1ffD7a , http://t.co/8eGBQGn
PharmStar Pharmaceuticals Receives Updated Intellectual Property Appraisal Valued at $32 Million
Pharmstar Pharm (USOTC:PHAR)
Intraday Stock Chart
Today : Monday 9 May 2011
PharmStar Pharmaceuticals, Inc., (PINKSHEETS: PHAR) (the "Company"), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today announced that it has received an updated appraisal for the Company's intellectual property. The new report states that the intellectual property associated with the patent, know-how and trademark positions of PharmStar Pharmaceuticals is valued at $32 million
. The report was filed as a supplemental information disclosure with the OTC Markets on May 6, 2011 and may be found at www.otcmarkets.com/stock/PHAR/financials, under the "Supplemental Information -- PharmStar IP Valuation."
The appraisal report was provided by Hultquist IP, a firm that represents clients in intellectual property matters in a wide variety of technologies, including: chemical, biological, electronic, solid-state, mechanical, and information technologies. According to the Hultquist report, "This total present value of $32 million is determined to be the value of the intellectual property rights associated with the Aquaprin™ product and the Insta-prin™ applicator product, since in the absence of the intellectual property applicable to these products, commercialization would not be viable, and there would be no barrier to entry to far larger competitors with correspondingly larger resources. The exclusionary rights associated with the proprietary patent position of PSP, together with the branding trademarks, and substantial know-how of Howard Phykitt, warrant such valuation. We therefore conclude that the intellectual property rights relating to the Aquaprin™ product and the Insta-prin™ applicator product are fairly valued at $32 million."
On April 28, 2011, the Company filed its Quarterly Report for the first quarter of 2011. In the report, the Company recognized the value of its Intellectual Property and Patents, Research and Development of Patents at a total of $13,104,549. The Company will continue to list these assets at their imputed book value, rather than the determined market value pursuant to the report.
"Though we are pleased with the valuation ascribed to the Aquaprin™ product line by Hultquist IP, we believe that the prudent course of action at this time is to continue to show the value of our core assets at book value. We will do so until such a time as the Company is in full production, or has a clear and substantial reason to modify the said valuation," stated Howard Phykitt, Chairman and CEO of PharmStar.
About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Rocky Mount, NC. For more information, visit www.pharmstarinc.com.
PHAR Financials out before yesterdays close showing
31M assets 50k liabilities
12m float as of 4-8
Clean balance sheet
FDA Approved "Aquaprin"
also..
Just upgraded to Pinksheets "Current Information" 4-14
Buying a NEW FDA Approved facility
CEO has put in writing NO DILUTION for at least 6 mos(HUGE)
Insiders shares restricted for min 1yr(awesome)
Quote:
The Company has received an offer to purchase the building, and is currently assessing the offer. Mr. Phykitt concluded, "I made a commitment to shareholders when we restructured the capitalization table that the Company has no need to dilute its common stock for at least the next six months. This decision will not affect that commitment."
http://ih.advfn.com/p.php?pid=nmona&article=47333789
3.There is no need to increase Authorized Shares at this time, and the company does not anticipate having to increase its Authorized anytime in the near future.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62802709
just look under Liabilities:
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=48798
Accounts payable-0-
Notes payable-0-
Notes payable to related parties-0-
Legal fees payable-0-
Licenses deposit Pharma Cap= 50,000
The ONLY Liability that Pharmstar has PERIOD is a $50,000 licensing fee for a Pharma bottle cap for the companies Instaprin product.
Why PHAR seen here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62514099
http://www.pharmstarinc.com/why_aquaprin.html
News***PHAR .023X.025 3X2
PHAR= RUNNING on NEWS = +20%
PHAR(.021) NEWS OUT NOW!!!
Quote:
PharmStar will begin moving into the new facility immediately, and has been preparing for the move over the last 30 days. PharmStar CEO Howard Phykitt founded Granutec, Inc. in 1985 in Wilson, NC before selling the company in 1989. He remained with the company through 1991. Mr. Phykitt then started Health Corporation , developing and marketing the original form of Aquaprin.
The Company did not issue any type of a new debt instrument, nor did the Company dilute its existing common share capital structure in order to finance the transaction, which is consistent with the company's objective of minimizing future dilution of its shareholder base.
http://finance.yahoo.com/news/PharmStar-Pharmaceuticals-Inc-iw-2427996609.html?x=0
-----------------------------
PHAR Property Appraisal Valued at $32 Million
Date : 05/09/2011 @ 1:21PM
Source : MarketWire
Stock : PharmStar Pharmaceuticals, Inc. (PHAR)
Quote : 0.032 0.002 (6.67%) @ 2:02PM
http://news.morningstar.com/all/market-wire/11753738/pharmstar-pharmaceuticals-receives-updated-intellectual-property-appraisal-valued-at-32-million.aspx
((wow~DD))= http://t.co/k1ffD7a , http://t.co/8eGBQGn
PharmStar Pharmaceuticals Receives Updated Intellectual Property Appraisal Valued at $32 Million
Pharmstar Pharm (USOTC:PHAR)
Intraday Stock Chart
Today : Monday 9 May 2011
PharmStar Pharmaceuticals, Inc., (PINKSHEETS: PHAR) (the "Company"), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today announced that it has received an updated appraisal for the Company's intellectual property. The new report states that the intellectual property associated with the patent, know-how and trademark positions of PharmStar Pharmaceuticals is valued at $32 million
. The report was filed as a supplemental information disclosure with the OTC Markets on May 6, 2011 and may be found at www.otcmarkets.com/stock/PHAR/financials, under the "Supplemental Information -- PharmStar IP Valuation."
The appraisal report was provided by Hultquist IP, a firm that represents clients in intellectual property matters in a wide variety of technologies, including: chemical, biological, electronic, solid-state, mechanical, and information technologies. According to the Hultquist report, "This total present value of $32 million is determined to be the value of the intellectual property rights associated with the Aquaprin™ product and the Insta-prin™ applicator product, since in the absence of the intellectual property applicable to these products, commercialization would not be viable, and there would be no barrier to entry to far larger competitors with correspondingly larger resources. The exclusionary rights associated with the proprietary patent position of PSP, together with the branding trademarks, and substantial know-how of Howard Phykitt, warrant such valuation. We therefore conclude that the intellectual property rights relating to the Aquaprin™ product and the Insta-prin™ applicator product are fairly valued at $32 million."
On April 28, 2011, the Company filed its Quarterly Report for the first quarter of 2011. In the report, the Company recognized the value of its Intellectual Property and Patents, Research and Development of Patents at a total of $13,104,549. The Company will continue to list these assets at their imputed book value, rather than the determined market value pursuant to the report.
"Though we are pleased with the valuation ascribed to the Aquaprin™ product line by Hultquist IP, we believe that the prudent course of action at this time is to continue to show the value of our core assets at book value. We will do so until such a time as the Company is in full production, or has a clear and substantial reason to modify the said valuation," stated Howard Phykitt, Chairman and CEO of PharmStar.
About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Rocky Mount, NC. For more information, visit www.pharmstarinc.com.
PHAR Financials out before yesterdays close showing
31M assets 50k liabilities
12m float as of 4-8
Clean balance sheet
FDA Approved "Aquaprin"
also..
Just upgraded to Pinksheets "Current Information" 4-14
Buying a NEW FDA Approved facility
CEO has put in writing NO DILUTION for at least 6 mos(HUGE)
Insiders shares restricted for min 1yr(awesome)
Quote:
The Company has received an offer to purchase the building, and is currently assessing the offer. Mr. Phykitt concluded, "I made a commitment to shareholders when we restructured the capitalization table that the Company has no need to dilute its common stock for at least the next six months. This decision will not affect that commitment."
http://ih.advfn.com/p.php?pid=nmona&article=47333789
3.There is no need to increase Authorized Shares at this time, and the company does not anticipate having to increase its Authorized anytime in the near future.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62802709
just look under Liabilities:
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=48798
Accounts payable-0-
Notes payable-0-
Notes payable to related parties-0-
Legal fees payable-0-
Licenses deposit Pharma Cap= 50,000
The ONLY Liability that Pharmstar has PERIOD is a $50,000 licensing fee for a Pharma bottle cap for the companies Instaprin product.
Why PHAR seen here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62514099
http://www.pharmstarinc.com/why_aquaprin.html
News***PHAR .023X.025 3X2
PHAR= RUNNING on NEWS = +20%
PHAR(.021) NEWS OUT NOW!!!
Quote:
PharmStar will begin moving into the new facility immediately, and has been preparing for the move over the last 30 days. PharmStar CEO Howard Phykitt founded Granutec, Inc. in 1985 in Wilson, NC before selling the company in 1989. He remained with the company through 1991. Mr. Phykitt then started Health Corporation , developing and marketing the original form of Aquaprin.
The Company did not issue any type of a new debt instrument, nor did the Company dilute its existing common share capital structure in order to finance the transaction, which is consistent with the company's objective of minimizing future dilution of its shareholder base.
http://finance.yahoo.com/news/PharmStar-Pharmaceuticals-Inc-iw-2427996609.html?x=0
-----------------------------
PHAR Property Appraisal Valued at $32 Million
Date : 05/09/2011 @ 1:21PM
Source : MarketWire
Stock : PharmStar Pharmaceuticals, Inc. (PHAR)
Quote : 0.032 0.002 (6.67%) @ 2:02PM
http://news.morningstar.com/all/market-wire/11753738/pharmstar-pharmaceuticals-receives-updated-intellectual-property-appraisal-valued-at-32-million.aspx
((wow~DD))= http://t.co/k1ffD7a , http://t.co/8eGBQGn
PharmStar Pharmaceuticals Receives Updated Intellectual Property Appraisal Valued at $32 Million
Pharmstar Pharm (USOTC:PHAR)
Intraday Stock Chart
Today : Monday 9 May 2011
PharmStar Pharmaceuticals, Inc., (PINKSHEETS: PHAR) (the "Company"), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today announced that it has received an updated appraisal for the Company's intellectual property. The new report states that the intellectual property associated with the patent, know-how and trademark positions of PharmStar Pharmaceuticals is valued at $32 million
. The report was filed as a supplemental information disclosure with the OTC Markets on May 6, 2011 and may be found at www.otcmarkets.com/stock/PHAR/financials, under the "Supplemental Information -- PharmStar IP Valuation."
The appraisal report was provided by Hultquist IP, a firm that represents clients in intellectual property matters in a wide variety of technologies, including: chemical, biological, electronic, solid-state, mechanical, and information technologies. According to the Hultquist report, "This total present value of $32 million is determined to be the value of the intellectual property rights associated with the Aquaprin™ product and the Insta-prin™ applicator product, since in the absence of the intellectual property applicable to these products, commercialization would not be viable, and there would be no barrier to entry to far larger competitors with correspondingly larger resources. The exclusionary rights associated with the proprietary patent position of PSP, together with the branding trademarks, and substantial know-how of Howard Phykitt, warrant such valuation. We therefore conclude that the intellectual property rights relating to the Aquaprin™ product and the Insta-prin™ applicator product are fairly valued at $32 million."
On April 28, 2011, the Company filed its Quarterly Report for the first quarter of 2011. In the report, the Company recognized the value of its Intellectual Property and Patents, Research and Development of Patents at a total of $13,104,549. The Company will continue to list these assets at their imputed book value, rather than the determined market value pursuant to the report.
"Though we are pleased with the valuation ascribed to the Aquaprin™ product line by Hultquist IP, we believe that the prudent course of action at this time is to continue to show the value of our core assets at book value. We will do so until such a time as the Company is in full production, or has a clear and substantial reason to modify the said valuation," stated Howard Phykitt, Chairman and CEO of PharmStar.
About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Rocky Mount, NC. For more information, visit www.pharmstarinc.com.
PHAR Financials out before yesterdays close showing
31M assets 50k liabilities
12m float as of 4-8
Clean balance sheet
FDA Approved "Aquaprin"
also..
Just upgraded to Pinksheets "Current Information" 4-14
Buying a NEW FDA Approved facility
CEO has put in writing NO DILUTION for at least 6 mos(HUGE)
Insiders shares restricted for min 1yr(awesome)
Quote:
The Company has received an offer to purchase the building, and is currently assessing the offer. Mr. Phykitt concluded, "I made a commitment to shareholders when we restructured the capitalization table that the Company has no need to dilute its common stock for at least the next six months. This decision will not affect that commitment."
http://ih.advfn.com/p.php?pid=nmona&article=47333789
3.There is no need to increase Authorized Shares at this time, and the company does not anticipate having to increase its Authorized anytime in the near future.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62802709
just look under Liabilities:
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=48798
Accounts payable-0-
Notes payable-0-
Notes payable to related parties-0-
Legal fees payable-0-
Licenses deposit Pharma Cap= 50,000
The ONLY Liability that Pharmstar has PERIOD is a $50,000 licensing fee for a Pharma bottle cap for the companies Instaprin product.
Why PHAR seen here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62514099
http://www.pharmstarinc.com/why_aquaprin.html
News***PHAR .023X.025 3X2
PHAR= RUNNING on NEWS = +20%
PHAR(.021) NEWS OUT NOW!!!
Quote:
PharmStar will begin moving into the new facility immediately, and has been preparing for the move over the last 30 days. PharmStar CEO Howard Phykitt founded Granutec, Inc. in 1985 in Wilson, NC before selling the company in 1989. He remained with the company through 1991. Mr. Phykitt then started Health Corporation , developing and marketing the original form of Aquaprin.
The Company did not issue any type of a new debt instrument, nor did the Company dilute its existing common share capital structure in order to finance the transaction, which is consistent with the company's objective of minimizing future dilution of its shareholder base.
http://finance.yahoo.com/news/PharmStar-Pharmaceuticals-Inc-iw-2427996609.html?x=0
-----------------------------
PHAR Property Appraisal Valued at $32 Million
Date : 05/09/2011 @ 1:21PM
Source : MarketWire
Stock : PharmStar Pharmaceuticals, Inc. (PHAR)
Quote : 0.032 0.002 (6.67%) @ 2:02PM
http://news.morningstar.com/all/market-wire/11753738/pharmstar-pharmaceuticals-receives-updated-intellectual-property-appraisal-valued-at-32-million.aspx
((wow~DD))= http://t.co/k1ffD7a , http://t.co/8eGBQGn
PharmStar Pharmaceuticals Receives Updated Intellectual Property Appraisal Valued at $32 Million
Pharmstar Pharm (USOTC:PHAR)
Intraday Stock Chart
Today : Monday 9 May 2011
PharmStar Pharmaceuticals, Inc., (PINKSHEETS: PHAR) (the "Company"), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today announced that it has received an updated appraisal for the Company's intellectual property. The new report states that the intellectual property associated with the patent, know-how and trademark positions of PharmStar Pharmaceuticals is valued at $32 million
. The report was filed as a supplemental information disclosure with the OTC Markets on May 6, 2011 and may be found at www.otcmarkets.com/stock/PHAR/financials, under the "Supplemental Information -- PharmStar IP Valuation."
The appraisal report was provided by Hultquist IP, a firm that represents clients in intellectual property matters in a wide variety of technologies, including: chemical, biological, electronic, solid-state, mechanical, and information technologies. According to the Hultquist report, "This total present value of $32 million is determined to be the value of the intellectual property rights associated with the Aquaprin™ product and the Insta-prin™ applicator product, since in the absence of the intellectual property applicable to these products, commercialization would not be viable, and there would be no barrier to entry to far larger competitors with correspondingly larger resources. The exclusionary rights associated with the proprietary patent position of PSP, together with the branding trademarks, and substantial know-how of Howard Phykitt, warrant such valuation. We therefore conclude that the intellectual property rights relating to the Aquaprin™ product and the Insta-prin™ applicator product are fairly valued at $32 million."
On April 28, 2011, the Company filed its Quarterly Report for the first quarter of 2011. In the report, the Company recognized the value of its Intellectual Property and Patents, Research and Development of Patents at a total of $13,104,549. The Company will continue to list these assets at their imputed book value, rather than the determined market value pursuant to the report.
"Though we are pleased with the valuation ascribed to the Aquaprin™ product line by Hultquist IP, we believe that the prudent course of action at this time is to continue to show the value of our core assets at book value. We will do so until such a time as the Company is in full production, or has a clear and substantial reason to modify the said valuation," stated Howard Phykitt, Chairman and CEO of PharmStar.
About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Rocky Mount, NC. For more information, visit www.pharmstarinc.com.
PHAR Financials out before yesterdays close showing
31M assets 50k liabilities
12m float as of 4-8
Clean balance sheet
FDA Approved "Aquaprin"
also..
Just upgraded to Pinksheets "Current Information" 4-14
Buying a NEW FDA Approved facility
CEO has put in writing NO DILUTION for at least 6 mos(HUGE)
Insiders shares restricted for min 1yr(awesome)
Quote:
The Company has received an offer to purchase the building, and is currently assessing the offer. Mr. Phykitt concluded, "I made a commitment to shareholders when we restructured the capitalization table that the Company has no need to dilute its common stock for at least the next six months. This decision will not affect that commitment."
http://ih.advfn.com/p.php?pid=nmona&article=47333789
3.There is no need to increase Authorized Shares at this time, and the company does not anticipate having to increase its Authorized anytime in the near future.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62802709
just look under Liabilities:
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=48798
Accounts payable-0-
Notes payable-0-
Notes payable to related parties-0-
Legal fees payable-0-
Licenses deposit Pharma Cap= 50,000
The ONLY Liability that Pharmstar has PERIOD is a $50,000 licensing fee for a Pharma bottle cap for the companies Instaprin product.
Why PHAR seen here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62514099
http://www.pharmstarinc.com/why_aquaprin.html
News***PHAR .023X.025 3X2
PHAR= RUNNING on NEWS = +20%
PHAR(.021) NEWS OUT NOW!!!
Quote:
PharmStar will begin moving into the new facility immediately, and has been preparing for the move over the last 30 days. PharmStar CEO Howard Phykitt founded Granutec, Inc. in 1985 in Wilson, NC before selling the company in 1989. He remained with the company through 1991. Mr. Phykitt then started Health Corporation , developing and marketing the original form of Aquaprin.
The Company did not issue any type of a new debt instrument, nor did the Company dilute its existing common share capital structure in order to finance the transaction, which is consistent with the company's objective of minimizing future dilution of its shareholder base.
http://finance.yahoo.com/news/PharmStar-Pharmaceuticals-Inc-iw-2427996609.html?x=0
-----------------------------
PHAR Property Appraisal Valued at $32 Million
Date : 05/09/2011 @ 1:21PM
Source : MarketWire
Stock : PharmStar Pharmaceuticals, Inc. (PHAR)
Quote : 0.032 0.002 (6.67%) @ 2:02PM
http://news.morningstar.com/all/market-wire/11753738/pharmstar-pharmaceuticals-receives-updated-intellectual-property-appraisal-valued-at-32-million.aspx
((wow~DD))= http://t.co/k1ffD7a , http://t.co/8eGBQGn
PharmStar Pharmaceuticals Receives Updated Intellectual Property Appraisal Valued at $32 Million
Pharmstar Pharm (USOTC:PHAR)
Intraday Stock Chart
Today : Monday 9 May 2011
PharmStar Pharmaceuticals, Inc., (PINKSHEETS: PHAR) (the "Company"), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today announced that it has received an updated appraisal for the Company's intellectual property. The new report states that the intellectual property associated with the patent, know-how and trademark positions of PharmStar Pharmaceuticals is valued at $32 million
. The report was filed as a supplemental information disclosure with the OTC Markets on May 6, 2011 and may be found at www.otcmarkets.com/stock/PHAR/financials, under the "Supplemental Information -- PharmStar IP Valuation."
The appraisal report was provided by Hultquist IP, a firm that represents clients in intellectual property matters in a wide variety of technologies, including: chemical, biological, electronic, solid-state, mechanical, and information technologies. According to the Hultquist report, "This total present value of $32 million is determined to be the value of the intellectual property rights associated with the Aquaprin™ product and the Insta-prin™ applicator product, since in the absence of the intellectual property applicable to these products, commercialization would not be viable, and there would be no barrier to entry to far larger competitors with correspondingly larger resources. The exclusionary rights associated with the proprietary patent position of PSP, together with the branding trademarks, and substantial know-how of Howard Phykitt, warrant such valuation. We therefore conclude that the intellectual property rights relating to the Aquaprin™ product and the Insta-prin™ applicator product are fairly valued at $32 million."
On April 28, 2011, the Company filed its Quarterly Report for the first quarter of 2011. In the report, the Company recognized the value of its Intellectual Property and Patents, Research and Development of Patents at a total of $13,104,549. The Company will continue to list these assets at their imputed book value, rather than the determined market value pursuant to the report.
"Though we are pleased with the valuation ascribed to the Aquaprin™ product line by Hultquist IP, we believe that the prudent course of action at this time is to continue to show the value of our core assets at book value. We will do so until such a time as the Company is in full production, or has a clear and substantial reason to modify the said valuation," stated Howard Phykitt, Chairman and CEO of PharmStar.
About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Rocky Mount, NC. For more information, visit www.pharmstarinc.com.
PHAR Financials out before yesterdays close showing
31M assets 50k liabilities
12m float as of 4-8
Clean balance sheet
FDA Approved "Aquaprin"
also..
Just upgraded to Pinksheets "Current Information" 4-14
Buying a NEW FDA Approved facility
CEO has put in writing NO DILUTION for at least 6 mos(HUGE)
Insiders shares restricted for min 1yr(awesome)
Quote:
The Company has received an offer to purchase the building, and is currently assessing the offer. Mr. Phykitt concluded, "I made a commitment to shareholders when we restructured the capitalization table that the Company has no need to dilute its common stock for at least the next six months. This decision will not affect that commitment."
http://ih.advfn.com/p.php?pid=nmona&article=47333789
3.There is no need to increase Authorized Shares at this time, and the company does not anticipate having to increase its Authorized anytime in the near future.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62802709
just look under Liabilities:
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=48798
Accounts payable-0-
Notes payable-0-
Notes payable to related parties-0-
Legal fees payable-0-
Licenses deposit Pharma Cap= 50,000
The ONLY Liability that Pharmstar has PERIOD is a $50,000 licensing fee for a Pharma bottle cap for the companies Instaprin product.
Why PHAR seen here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62514099
http://www.pharmstarinc.com/why_aquaprin.html
News***PHAR .023X.025 3X2
PHAR= RUNNING on NEWS = +20%
PHAR(.021) NEWS OUT NOW!!!
Quote:
PharmStar will begin moving into the new facility immediately, and has been preparing for the move over the last 30 days. PharmStar CEO Howard Phykitt founded Granutec, Inc. in 1985 in Wilson, NC before selling the company in 1989. He remained with the company through 1991. Mr. Phykitt then started Health Corporation , developing and marketing the original form of Aquaprin.
The Company did not issue any type of a new debt instrument, nor did the Company dilute its existing common share capital structure in order to finance the transaction, which is consistent with the company's objective of minimizing future dilution of its shareholder base.
http://finance.yahoo.com/news/PharmStar-Pharmaceuticals-Inc-iw-2427996609.html?x=0
-----------------------------
PHAR Property Appraisal Valued at $32 Million
Date : 05/09/2011 @ 1:21PM
Source : MarketWire
Stock : PharmStar Pharmaceuticals, Inc. (PHAR)
Quote : 0.032 0.002 (6.67%) @ 2:02PM
http://news.morningstar.com/all/market-wire/11753738/pharmstar-pharmaceuticals-receives-updated-intellectual-property-appraisal-valued-at-32-million.aspx
((wow~DD))= http://t.co/k1ffD7a , http://t.co/8eGBQGn
PharmStar Pharmaceuticals Receives Updated Intellectual Property Appraisal Valued at $32 Million
Pharmstar Pharm (USOTC:PHAR)
Intraday Stock Chart
Today : Monday 9 May 2011
PharmStar Pharmaceuticals, Inc., (PINKSHEETS: PHAR) (the "Company"), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today announced that it has received an updated appraisal for the Company's intellectual property. The new report states that the intellectual property associated with the patent, know-how and trademark positions of PharmStar Pharmaceuticals is valued at $32 million
. The report was filed as a supplemental information disclosure with the OTC Markets on May 6, 2011 and may be found at www.otcmarkets.com/stock/PHAR/financials, under the "Supplemental Information -- PharmStar IP Valuation."
The appraisal report was provided by Hultquist IP, a firm that represents clients in intellectual property matters in a wide variety of technologies, including: chemical, biological, electronic, solid-state, mechanical, and information technologies. According to the Hultquist report, "This total present value of $32 million is determined to be the value of the intellectual property rights associated with the Aquaprin™ product and the Insta-prin™ applicator product, since in the absence of the intellectual property applicable to these products, commercialization would not be viable, and there would be no barrier to entry to far larger competitors with correspondingly larger resources. The exclusionary rights associated with the proprietary patent position of PSP, together with the branding trademarks, and substantial know-how of Howard Phykitt, warrant such valuation. We therefore conclude that the intellectual property rights relating to the Aquaprin™ product and the Insta-prin™ applicator product are fairly valued at $32 million."
On April 28, 2011, the Company filed its Quarterly Report for the first quarter of 2011. In the report, the Company recognized the value of its Intellectual Property and Patents, Research and Development of Patents at a total of $13,104,549. The Company will continue to list these assets at their imputed book value, rather than the determined market value pursuant to the report.
"Though we are pleased with the valuation ascribed to the Aquaprin™ product line by Hultquist IP, we believe that the prudent course of action at this time is to continue to show the value of our core assets at book value. We will do so until such a time as the Company is in full production, or has a clear and substantial reason to modify the said valuation," stated Howard Phykitt, Chairman and CEO of PharmStar.
About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Rocky Mount, NC. For more information, visit www.pharmstarinc.com.
PHAR Financials out before yesterdays close showing
31M assets 50k liabilities
12m float as of 4-8
Clean balance sheet
FDA Approved "Aquaprin"
also..
Just upgraded to Pinksheets "Current Information" 4-14
Buying a NEW FDA Approved facility
CEO has put in writing NO DILUTION for at least 6 mos(HUGE)
Insiders shares restricted for min 1yr(awesome)
Quote:
The Company has received an offer to purchase the building, and is currently assessing the offer. Mr. Phykitt concluded, "I made a commitment to shareholders when we restructured the capitalization table that the Company has no need to dilute its common stock for at least the next six months. This decision will not affect that commitment."
http://ih.advfn.com/p.php?pid=nmona&article=47333789
3.There is no need to increase Authorized Shares at this time, and the company does not anticipate having to increase its Authorized anytime in the near future.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62802709
just look under Liabilities:
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=48798
Accounts payable-0-
Notes payable-0-
Notes payable to related parties-0-
Legal fees payable-0-
Licenses deposit Pharma Cap= 50,000
The ONLY Liability that Pharmstar has PERIOD is a $50,000 licensing fee for a Pharma bottle cap for the companies Instaprin product.
Why PHAR seen here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62514099
http://www.pharmstarinc.com/why_aquaprin.html
PHAR we may see a run to cover on short positions here. In return PPS goes up and with good news out new investors in. I would like to see a steady increase and not a shoot up and crash back down.But hey this is penny land where anything and everything can and will happen.
PHAR no joke last night I prayed for a substantial press release. I can see a multiple day PPS increase here as we will see shorts being covered. I see buying volume and chasing of the ASK